31-Gene Expression Profile Testing in Cutaneous Melanoma and Survival Outcomes in a Population-Based Analysis: A SEER Collaboration

Christine N. Bailey; Brian J. Martin; Valentina I. Petkov; Nicola C. Schussler; Jennifer L. Stevens; Suzanne Bentler; Rosemary D. Cress; Jennifer A. Doherty; Eric B. Durbin; Scarlett L. Gomez; Lou Gonsalves; Brenda Y. Hernandez; Lihua Liu; Bozena M. Morawski; Maria J. Schymura; Stephen M. Schwartz; Kevin C. Ward; Charles Wiggins; Xiao Cheng Wu; Matthew S. Goldberg; Jennifer J. Siegel; Robert W. Cook; Kyle R. Covington; Sarah J. Kurley

doi:10.1200/PO.23.00044

31-Gene Expression Profile Testing in Cutaneous Melanoma and Survival Outcomes in a Population-Based Analysis: A SEER Collaboration

Christine N. Bailey, Brian J. Martin, Valentina I. Petkov, Nicola C. Schussler, Jennifer L. Stevens, Suzanne Bentler, Rosemary D. Cress, Jennifer A. Doherty, Eric B. Durbin, Scarlett L. Gomez, Lou Gonsalves, Brenda Y. Hernandez, Lihua Liu, Bozena M. Morawski, Maria J. Schymura, Stephen M. Schwartz, Kevin C. Ward, Charles Wiggins, Xiao Cheng Wu, Matthew S. GoldbergJennifer J. Siegel, Robert W. Cook, Kyle R. Covington, Sarah J. Kurley

Research output: Contribution to journal › Article › peer-review

31 Scopus citations

Abstract

PURPOSEThe DecisionDx-Melanoma 31-gene expression profile (31-GEP) test is validated to classify cutaneous malignant melanoma (CM) patient risk of recurrence, metastasis, or death as low (class 1A), intermediate (class 1B/2A), or high (class 2B). This study aimed to examine the effect of 31-GEP testing on survival outcomes and confirm the prognostic ability of the 31-GEP at the population level.METHODSPatients with stage I-III CM with a clinical 31-GEP result between 2016 and 2018 were linked to data from 17 SEER registries (n = 4,687) following registries' operation procedures for linkages. Melanoma-specific survival (MSS) and overall survival (OS) differences by 31-GEP risk category were examined using Kaplan-Meier analysis and the log-rank test. Crude and adjusted hazard ratios (HRs) were calculated using Cox regression model to evaluate variables associated with survival. 31-GEP tested patients were propensity score-matched to a cohort of non-31-GEP tested patients from the SEER database. Robustness of the effect of 31-GEP testing was assessed using resampling.RESULTSPatients with a 31-GEP class 1A result had higher 3-year MSS and OS than patients with a class 1B/2A or class 2B result (MSS: 99.7% v 97.1% v 89.6%, P <.001; OS: 96.6% v 90.2% v 79.4%, P <.001). A class 2B result was an independent predictor of MSS (HR, 7.00; 95% CI, 2.70 to 18.00) and OS (HR, 2.39; 95% CI, 1.54 to 3.70). 31-GEP testing was associated with a 29% lower MSS mortality (HR, 0.71; 95% CI, 0.53 to 0.94) and 17% lower overall mortality (HR, 0.83; 95% CI, 0.70 to 0.99) relative to untested patients.CONCLUSIONIn a population-based, clinically tested melanoma cohort, the 31-GEP stratified patients by their risk of dying from melanoma.

Original language	English
Article number	e2300044
Journal	JCO Precision Oncology
Volume	7
DOIs	https://doi.org/10.1200/PO.23.00044
State	Published - 2023

Bibliographical note

Publisher Copyright:
© 2023 American Society of Clinical Oncology.

Funding

S.B.: Iowa Cancer Registry, through National Cancer Institute, Surveillance, Epidemiology and End Results Program Contract Award No. HHSN261201800012I_HHSN26100001. R.D.C.: Public Health Institute, Cancer Registry of Greater California, through National Cancer Institute, Surveillance, Epidemiology and End Results Program Contract Award No. HHSN261201800009I. J.A.D.: HCI Cancer Control and Population Sciences Program, through National Cancer Institute, Surveillance, Epidemiology and End Results Program Contract Award HHSN261201800016I. E.B.D.: Kentucky Cancer Registry, through National Cancer Institute, Surveillance, Epidemiology and End Results Program Contract Award No. HHSN261201800013I. S.L.G.: University of California, San Francisco, CA through National Cancer Institute, Surveillance, Epidemiology and End Results Program Contract Award HHSN261201800032I. L.G.: The Connecticut Tumor Registry is supported by Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract no. HHSN261201800002I. B.Y.H.: University of Hawaii Cancer Center, HI through National Cancer Institute, Surveillance, Epidemiology and End Results Program Contract Award HHSN261201300009I. L.L.: Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA through National Cancer Institute, Surveillance, Epidemiology and End Results Program Contract Award HHSN261201800032I. B.M.M.: Cancer Data Registry of Idaho, Idaho Hospital Association, Boise, Idaho through National Cancer Institute, Surveillance, Epidemiology and End Results Program Contract Award HHSN261201800006I and Centers for Disease Control and Prevention 1NU58DP006270. M.J.S.: Bureau of Cancer Epidemiology, New York State Department of Health, Albany, NY through National Cancer Institute, Surveillance, Epidemiology and End Results Program Contract Award HHSN261201800005I and Centers for Disease Control and Prevention NU58DP006309. S.M.S.: Division of Public Health Sciences Fred Hutchinson Cancer Center, through National Cancer Institute, Surveillance, Epidemiology and End Results Program Contract Award HHSN2612018000041. K.C.W.: Emory University, Atlanta GA. through National Cancer Institute, Surveillance, Epidemiology and End Results Program Contract Award HHSN261201800003I and Centers for Disease Control and Prevention 6NU58DP006352-05-01. C.W.: Emory University, Atlanta, GA, through National Cancer Institute, Surveillance, Epidemiology and End Results Program Contract Award HHSN261201800014I. X.W.: School of Public Health Louisiana State University Health New Orleans, through National Cancer Institute, Surveillance, Epidemiology and End Results Program Contract Award HHSN261201800007I/HHSN26100002.

Funders	Funder number
National Institutes of Health (NIH)
Institute of Public Health
Cancer Registry of Greater California	HHSN261201800009I
Cancer Registry of Greater California
National Childhood Cancer Registry – National Cancer Institute	HHSN261201800016I
National Childhood Cancer Registry – National Cancer Institute
Kentucky Cancer Registry	HHSN261201800032I, HHSN261201800013I
Louisiana State University School of Public Health	HHSN261201800007I/HHSN26100002
Bureau of Cancer Epidemiology, New York State Department of Health	HHSN2612018000041, 6NU58DP006352-05-01, NU58DP006309, HHSN261201800005I, HHSN261201800003I, HHSN261201800014I
Centers for Disease Control and Prevention	1NU58DP006270
Centers for Disease Control and Prevention
National Cancer Institute Surveillance Epidemiology and End Results Program	HHSN261201800012I_HHSN26100001
U.S. Department of Health and Human Services	HHSN261201300009I, HHSN261201800006I, HHSN261201800002I
U.S. Department of Health and Human Services

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1200/PO.23.00044

Cite this

Bailey, C. N., Martin, B. J., Petkov, V. I., Schussler, N. C., Stevens, J. L., Bentler, S., Cress, R. D., Doherty, J. A., Durbin, E. B., Gomez, S. L., Gonsalves, L., Hernandez, B. Y., Liu, L., Morawski, B. M., Schymura, M. J., Schwartz, S. M., Ward, K. C., Wiggins, C., Wu, X. C., ... Kurley, S. J. (2023). 31-Gene Expression Profile Testing in Cutaneous Melanoma and Survival Outcomes in a Population-Based Analysis: A SEER Collaboration. JCO Precision Oncology, 7, Article e2300044. https://doi.org/10.1200/PO.23.00044

@article{07b778512b0348d39aa623d181a926f6,

title = "31-Gene Expression Profile Testing in Cutaneous Melanoma and Survival Outcomes in a Population-Based Analysis: A SEER Collaboration",

abstract = "PURPOSEThe DecisionDx-Melanoma 31-gene expression profile (31-GEP) test is validated to classify cutaneous malignant melanoma (CM) patient risk of recurrence, metastasis, or death as low (class 1A), intermediate (class 1B/2A), or high (class 2B). This study aimed to examine the effect of 31-GEP testing on survival outcomes and confirm the prognostic ability of the 31-GEP at the population level.METHODSPatients with stage I-III CM with a clinical 31-GEP result between 2016 and 2018 were linked to data from 17 SEER registries (n = 4,687) following registries' operation procedures for linkages. Melanoma-specific survival (MSS) and overall survival (OS) differences by 31-GEP risk category were examined using Kaplan-Meier analysis and the log-rank test. Crude and adjusted hazard ratios (HRs) were calculated using Cox regression model to evaluate variables associated with survival. 31-GEP tested patients were propensity score-matched to a cohort of non-31-GEP tested patients from the SEER database. Robustness of the effect of 31-GEP testing was assessed using resampling.RESULTSPatients with a 31-GEP class 1A result had higher 3-year MSS and OS than patients with a class 1B/2A or class 2B result (MSS: 99.7\% v 97.1\% v 89.6\%, P <.001; OS: 96.6\% v 90.2\% v 79.4\%, P <.001). A class 2B result was an independent predictor of MSS (HR, 7.00; 95\% CI, 2.70 to 18.00) and OS (HR, 2.39; 95\% CI, 1.54 to 3.70). 31-GEP testing was associated with a 29\% lower MSS mortality (HR, 0.71; 95\% CI, 0.53 to 0.94) and 17\% lower overall mortality (HR, 0.83; 95\% CI, 0.70 to 0.99) relative to untested patients.CONCLUSIONIn a population-based, clinically tested melanoma cohort, the 31-GEP stratified patients by their risk of dying from melanoma.",

author = "Bailey, \{Christine N.\} and Martin, \{Brian J.\} and Petkov, \{Valentina I.\} and Schussler, \{Nicola C.\} and Stevens, \{Jennifer L.\} and Suzanne Bentler and Cress, \{Rosemary D.\} and Doherty, \{Jennifer A.\} and Durbin, \{Eric B.\} and Gomez, \{Scarlett L.\} and Lou Gonsalves and Hernandez, \{Brenda Y.\} and Lihua Liu and Morawski, \{Bozena M.\} and Schymura, \{Maria J.\} and Schwartz, \{Stephen M.\} and Ward, \{Kevin C.\} and Charles Wiggins and Wu, \{Xiao Cheng\} and Goldberg, \{Matthew S.\} and Siegel, \{Jennifer J.\} and Cook, \{Robert W.\} and Covington, \{Kyle R.\} and Kurley, \{Sarah J.\}",

note = "Publisher Copyright: {\textcopyright} 2023 American Society of Clinical Oncology.",

year = "2023",

doi = "10.1200/PO.23.00044",

language = "English",

volume = "7",

}

Bailey, CN, Martin, BJ, Petkov, VI, Schussler, NC, Stevens, JL, Bentler, S, Cress, RD, Doherty, JA, Durbin, EB, Gomez, SL, Gonsalves, L, Hernandez, BY, Liu, L, Morawski, BM, Schymura, MJ, Schwartz, SM, Ward, KC, Wiggins, C, Wu, XC, Goldberg, MS, Siegel, JJ, Cook, RW, Covington, KR & Kurley, SJ 2023, '31-Gene Expression Profile Testing in Cutaneous Melanoma and Survival Outcomes in a Population-Based Analysis: A SEER Collaboration', JCO Precision Oncology, vol. 7, e2300044. https://doi.org/10.1200/PO.23.00044

TY - JOUR

T1 - 31-Gene Expression Profile Testing in Cutaneous Melanoma and Survival Outcomes in a Population-Based Analysis

T2 - A SEER Collaboration

AU - Bailey, Christine N.

AU - Martin, Brian J.

AU - Petkov, Valentina I.

AU - Schussler, Nicola C.

AU - Stevens, Jennifer L.

AU - Bentler, Suzanne

AU - Cress, Rosemary D.

AU - Doherty, Jennifer A.

AU - Durbin, Eric B.

AU - Gomez, Scarlett L.

AU - Gonsalves, Lou

AU - Hernandez, Brenda Y.

AU - Liu, Lihua

AU - Morawski, Bozena M.

AU - Schymura, Maria J.

AU - Schwartz, Stephen M.

AU - Ward, Kevin C.

AU - Wiggins, Charles

AU - Wu, Xiao Cheng

AU - Goldberg, Matthew S.

AU - Siegel, Jennifer J.

AU - Cook, Robert W.

AU - Covington, Kyle R.

AU - Kurley, Sarah J.

PY - 2023

Y1 - 2023

N2 - PURPOSEThe DecisionDx-Melanoma 31-gene expression profile (31-GEP) test is validated to classify cutaneous malignant melanoma (CM) patient risk of recurrence, metastasis, or death as low (class 1A), intermediate (class 1B/2A), or high (class 2B). This study aimed to examine the effect of 31-GEP testing on survival outcomes and confirm the prognostic ability of the 31-GEP at the population level.METHODSPatients with stage I-III CM with a clinical 31-GEP result between 2016 and 2018 were linked to data from 17 SEER registries (n = 4,687) following registries' operation procedures for linkages. Melanoma-specific survival (MSS) and overall survival (OS) differences by 31-GEP risk category were examined using Kaplan-Meier analysis and the log-rank test. Crude and adjusted hazard ratios (HRs) were calculated using Cox regression model to evaluate variables associated with survival. 31-GEP tested patients were propensity score-matched to a cohort of non-31-GEP tested patients from the SEER database. Robustness of the effect of 31-GEP testing was assessed using resampling.RESULTSPatients with a 31-GEP class 1A result had higher 3-year MSS and OS than patients with a class 1B/2A or class 2B result (MSS: 99.7% v 97.1% v 89.6%, P <.001; OS: 96.6% v 90.2% v 79.4%, P <.001). A class 2B result was an independent predictor of MSS (HR, 7.00; 95% CI, 2.70 to 18.00) and OS (HR, 2.39; 95% CI, 1.54 to 3.70). 31-GEP testing was associated with a 29% lower MSS mortality (HR, 0.71; 95% CI, 0.53 to 0.94) and 17% lower overall mortality (HR, 0.83; 95% CI, 0.70 to 0.99) relative to untested patients.CONCLUSIONIn a population-based, clinically tested melanoma cohort, the 31-GEP stratified patients by their risk of dying from melanoma.

AB - PURPOSEThe DecisionDx-Melanoma 31-gene expression profile (31-GEP) test is validated to classify cutaneous malignant melanoma (CM) patient risk of recurrence, metastasis, or death as low (class 1A), intermediate (class 1B/2A), or high (class 2B). This study aimed to examine the effect of 31-GEP testing on survival outcomes and confirm the prognostic ability of the 31-GEP at the population level.METHODSPatients with stage I-III CM with a clinical 31-GEP result between 2016 and 2018 were linked to data from 17 SEER registries (n = 4,687) following registries' operation procedures for linkages. Melanoma-specific survival (MSS) and overall survival (OS) differences by 31-GEP risk category were examined using Kaplan-Meier analysis and the log-rank test. Crude and adjusted hazard ratios (HRs) were calculated using Cox regression model to evaluate variables associated with survival. 31-GEP tested patients were propensity score-matched to a cohort of non-31-GEP tested patients from the SEER database. Robustness of the effect of 31-GEP testing was assessed using resampling.RESULTSPatients with a 31-GEP class 1A result had higher 3-year MSS and OS than patients with a class 1B/2A or class 2B result (MSS: 99.7% v 97.1% v 89.6%, P <.001; OS: 96.6% v 90.2% v 79.4%, P <.001). A class 2B result was an independent predictor of MSS (HR, 7.00; 95% CI, 2.70 to 18.00) and OS (HR, 2.39; 95% CI, 1.54 to 3.70). 31-GEP testing was associated with a 29% lower MSS mortality (HR, 0.71; 95% CI, 0.53 to 0.94) and 17% lower overall mortality (HR, 0.83; 95% CI, 0.70 to 0.99) relative to untested patients.CONCLUSIONIn a population-based, clinically tested melanoma cohort, the 31-GEP stratified patients by their risk of dying from melanoma.

UR - https://www.scopus.com/pages/publications/85179465195

UR - https://www.scopus.com/inward/citedby.url?scp=85179465195&partnerID=8YFLogxK

U2 - 10.1200/PO.23.00044

DO - 10.1200/PO.23.00044

M3 - Article

C2 - 37384864

AN - SCOPUS:85179465195

VL - 7

JO - JCO Precision Oncology

JF - JCO Precision Oncology

M1 - e2300044

ER -

31-Gene Expression Profile Testing in Cutaneous Melanoma and Survival Outcomes in a Population-Based Analysis: A SEER Collaboration

Abstract

Bibliographical note

Funding

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this